MAPC generation of muscle
The present invention relates to methods of increasing function and/or mass in damaged striated muscle tissue of interest (e.g., cardiac or muscle tissue) by providing of a population of multipotent adult progenitor cells (“MAPCs”), which effectively generate new striated muscle over time.
1. A method of providing striated muscle to a subject in need thereof, the method comprising administering to the subject, in amounts effective to provide new striated muscle, isolated human non-embryonic non-germ cells that do not express CD45 or glyA and express oct3/4, telomerase, rex-1, and rox-1, and are not transformed, wherein the subject has existing striated muscle, and wherein the isolated non-embryonic non-germ cells are expanded in cell culture medium prior to administration to the subject.
2. A method of increasing striated muscle mass, the method comprising contacting, in amounts effective to generate new striated muscle, isolated human non-embryonic non-germ cells that do not express CD45 or glyA and express oct3/4, telomerase, rex-1, and rox-1, and are not transformed, with existing striated muscle, and wherein the isolated non-embryonic non-germ cells are expanded in cell culture medium prior to administration to the subject.
3. A method for producing striated muscle cells in a subject, the method comprising administering to the subject, in amounts effective to produce striated muscle cells, isolated human non-embryonic non-germ cells that do not express CD45 or glyA and express oct3/4, telomerase, rex-1, and rox-1, and are not transformed, and wherein the isolated non-embryonic non-germ cells are expanded in cell culture medium prior to administration to the subject.
4. The method of claim 1 , wherein existing striated muscle in the subject is damaged by disease.
5. The method of claim 4 , wherein the disease is selected from the group consisting of congestive heart failure, coronary artery disease, myocardial infarction, myocardial ischemia, atherosclerosis, cardiomyopathy, idiopathic cardiomyopathy, cardiac arrhythmias, muscular dystrophy, muscle mass abnormalities, muscle degeneration, infective myocarditis, drug- and toxin-induced muscle abnormalities, hypersensitivity myocarditis, autoimmune endocarditis, and congenital heart disease.
6. The method of claim 1 or 2 , wherein the new striated muscle is cardiac muscle.
7. The method of claim 1 or 2 , wherein the new striated muscle is skeletal muscle.
8. The method of claim 1 or 3 , wherein the isolated non-embryonic non-germ cells are administered using techniques selected from the group consisting of surgical intramyocardial injection, transendocardial injection, intracoronary injection, transvascular injection, intramuscular injection, intravenous injection and cardiac catheter administration.
9. The method of claim 3 , wherein the striated muscle cells are cardiac muscle cells.
10. The method of claim 3 , wherein the striated muscle cells are skeletal muscle cells.
11. The method of claim 1 or 3 , wherein the subject is human.
12. The method of any one of claims 1 - 3 , wherein the non-embryonic non-germ cells are isolated from bone marrow, muscle, brain, spinal cord, blood or skin.
13. The method of claim 1 or 3 , wherein the non-embryonic non-germ cells are administered in the presence of cytokines, growth factors or a combination thereof.
14. The method of claim 1 or 3 , wherein the administered non-embryonic non-germ cells are autologous cells.
15. The method of claim 1 or 3 , wherein the administered non-embryonic non-germ cells are allogeneic cells.
16. The method of any of claims 1 - 3 wherein said isolated non-embryonic non-germ cells can differentiate into at least cell type of at least two of the mesodermal, endodermal, and ectodermal embryonic lineages.
17. The method of claim 16 wherein said non-embryonic non-germ cells can differentiate into at least one cell type of each of the endodermal, ectodermal and mesodermal lineages.